​

BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BBIO Stock Forecast

BridgeBio Pharma (BBIO) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $105.21, with a high of $157.00 and a low of $83.00. This represents a 55.45% increase from the last price of $67.68.

- $40 $80 $120 $160 $200 High: $157 Avg: $105.21 Low: $83 Last Closed Price: $67.68

BBIO Stock Rating

BridgeBio Pharma stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (92.31%), 2 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 2 24 0 Strong Sell Sell Hold Buy Strong Buy

BBIO Price Target Upside V Benchmarks

TypeNameUpside
StockBridgeBio Pharma55.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3829
Avg Price Target$104.00$107.00$95.38
Last Closing Price$67.68$67.68$67.68
Upside/Downside53.66%58.10%40.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 266152--23
May, 266161--23
Apr, 265161--22
Mar, 265151--21
Feb, 265151--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 03, 2026Canaccord Genuity$104.00$63.8862.81%53.66%
May 28, 2026Morgan Stanley$98.00$65.5949.41%44.80%
May 11, 2026H.C. Wainwright$110.00$67.3963.23%62.53%
May 08, 2026Evercore ISI$130.00$66.5395.40%92.08%
May 08, 2026Bernstein$114.00$67.4569.01%68.44%
Apr 29, 2026Danielle BrillTruist Financial$102.00$70.0845.55%50.71%
Apr 08, 2026Luca IssiRBC Capital$100.00$74.1434.88%47.75%
Mar 12, 2026Mani ForooharLeerink Partners$98.00$68.7742.50%44.80%
Feb 25, 2026Danielle BrillTruist Financial$95.00$65.7544.49%40.37%
Feb 17, 2026Raghuram SelvarajuH.C. Wainwright$100.00$75.2532.89%47.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 28, 2026Morgan StanleyOverweightOverweighthold
May 26, 2026Raymond JamesOutperformMarket Performdowngrade
May 18, 2026CitigroupBuyNeutralinitialise
May 11, 2026H.C. WainwrightBuyBuyhold
May 08, 2026Evercore ISIOutperformOutperformhold
May 08, 2026BernsteinOutperformOutperformhold
Apr 08, 2026RBC CapitalOutperforminitialise
Mar 12, 2026Leerink PartnersOutperformOutperformhold
Mar 10, 2026BarclaysOverweightOverweighthold
Mar 10, 2026William BlairOutperforminitialise

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.90$-3.35$-3.95$-2.88$-3.78---
Avg Forecast$-3.70$-3.13$-3.76$-2.52$-3.55$-2.51$-0.57$1.91
High Forecast$-1.53$-1.18$-3.60$-2.32$-2.63$-0.86$0.68$4.02
Low Forecast$-9.39$-7.28$-3.97$-2.70$-4.27$-3.28$-0.95$0.30
Surprise %5.41%7.03%5.05%14.29%6.48%---

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$69.72M$77.65M$9.30M$221.90M$362.37M---
Avg Forecast$78.26M$82.75M$12.29M$219.05M$176.98M$437.33M$967.67M$1.67B
High Forecast$170.79M$167.23M$16.09M$230.15M$313.43M$442.24M$1.01B$3.08B
Low Forecast$43.03M$43.07M$7.40M$214.98M$64.02M$432.43M$928.41M$588.98M
Surprise %-10.91%-6.16%-24.31%1.30%104.75%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-562.54M$-481.18M$-643.20M$-535.76M$-724.93M---
Avg Forecast$-450.77M$-570.76M$-643.20M$-438.86M$-561.83M$-336.28M$-21.66M$311.59M
High Forecast$-360.62M$-456.61M$-514.56M$-376.93M$-428.14M$-139.25M$110.71M$654.37M
Low Forecast$-540.92M$-684.91M$-771.84M$-439.49M$-695.53M$-533.31M$-154.03M$49.48M
Surprise %24.80%-15.69%-22.08%29.03%---

BBIO Forecast FAQ

Is BridgeBio Pharma stock a buy?

BridgeBio Pharma stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BridgeBio Pharma is a favorable investment for most analysts.

What is BridgeBio Pharma's price target?

BridgeBio Pharma's price target, set by 26 Wall Street analysts, averages $105.21 over the next 12 months. The price target range spans from $83 at the low end to $157 at the high end, suggesting a potential 55.45% change from the previous closing price of $67.68.

How does BridgeBio Pharma stock forecast compare to its benchmarks?

BridgeBio Pharma's stock forecast shows a 55.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BridgeBio Pharma over the past three months?

  • June 2026: 26.09% Strong Buy, 65.22% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 26.09% Strong Buy, 69.57% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 22.73% Strong Buy, 72.73% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.

What is BridgeBio Pharma’s EPS forecast?

BridgeBio Pharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.51, marking a -33.60% decrease from the reported $-3.78 in 2025. Estimates for the following years are $-0.57 in 2027, and $1.91 in 2028.

What is BridgeBio Pharma’s revenue forecast?

BridgeBio Pharma's average annual revenue forecast for its fiscal year ending in December 2026 is $437.33M, reflecting a 20.69% increase from the reported $362.37M in 2025. The forecast for 2027 is $967.67M, and $1.67B for 2028.

What is BridgeBio Pharma’s net income forecast?

BridgeBio Pharma's net income forecast for the fiscal year ending in December 2026 stands at $-336M, representing a -53.61% decrease from the reported $-725M in 2025. Projections indicate $-21.661M in 2027, and $311.59M in 2028.